Genentech is teaming with San Francisco ’s Adaptive Biotechnologies to develop cancer immunotherapies specific to individual patients. The latter uses scanning technology that can search the immune system for targets for cell therapies. Adaptive will check its library of T-cell receptors found by the tech to identify ones useful in therapies, which Genentech will then engineer and manufacture as part of the $ over $2bn partnership. Genentech could ultimately pay 300bn in milestones as the experimental therapies are developed. The Seattle -based group will also deal with clinical testing, commercialisation and regulatory work. Adaptive will receive royalties from any therapies reaching market.
Genentech is teaming with Seattle’s Adaptive Biotechnologies to develop cancer immunotherapies specific to individual patients. The latter uses scanning technology that can search the immune system for targets for cell therapies. Adaptive will check its library of T-cell receptors found by the tech to identify ones useful in therapies, which Genentech will then engineer and manufacture as part of the $300bn partnership. Genentech could ultimately pay over $2bn in milestones as the experimental therapies are developed. The San Francisco-based group will also deal with clinical testing, commercialisation and regulatory work. Adaptive will receive royalties from any therapies reaching market.